Want to see HURA full AI Analyst Report?
HURA Stock Chart & Stats
$2.04
-$0.03(-0.55%)
At close: 4:00 PM EST
$2.04
-$0.03(-0.55%)
Day’s Range― - ―
52-Week Range$0.41 - $3.43
Previous CloseN/A
Volume116.05K
Average Volume (3M)215.15K
Market Cap
$130.00M
Enterprise Value$152.96
Total Cash (Recent Filing)$995.98K
Total Debt (Recent Filing)$407.02K
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Nov 13, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding63,726,616
10 Day Avg. Volume212,396
30 Day Avg. Volume215,145
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.73
Price to Sales (P/S)0.00
P/FCF Ratio-1.31
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside341.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.56
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Positive EquityLow leverage and positive equity provide a stronger starting point for funding clinical development than a highly indebted balance sheet. This may preserve financing flexibility, although historical equity volatility shows that this strength is not assured.
Multi-Year Financing AccessThe five-year, $50 million revolving facility gives TuHURA access to capital for research and operations, potentially extending planning visibility. It supports development spending before commercial revenue exists, though borrowing increases future obligations.
Governance ContinuityDirector elections, auditor ratification and recurring governance approvals provide continuity in oversight and reporting. Stable governance can support execution of clinical and regulatory plans, although it does not eliminate the company’s funding risk.
Bears Say
No Commercial RevenueZero revenue across all reported periods confirms TuHURA remains pre-commercial and has no product-sales engine funding operations. Until a candidate reaches commercialization, the company must depend on clinical progress and external capital rather than recurring operating revenue.
Widening Net LossesNet losses have widened materially over multiple periods, increasing the resources required to advance the pipeline. Persistent losses reduce financial flexibility and heighten the amount of capital needed for costly clinical and regulatory development.
Persistent Cash BurnDeteriorating operating cash flow and roughly $29.9 million of negative TTM free cash flow indicate that operations consume substantial cash. This creates recurring financing needs and exposes the company to additional debt or equity issuance.
TuHURA Biosciences News
HURA FAQ
What was TuHURA Biosciences’s price range in the past 12 months?
TuHURA Biosciences lowest stock price was $0.41 and its highest was $3.43 in the past 12 months.
What is TuHURA Biosciences’s market cap?
TuHURA Biosciences’s market cap is $130.00M.
When is TuHURA Biosciences’s upcoming earnings report date?
TuHURA Biosciences’s upcoming earnings report date is Nov 13, 2026 which is in 77 days.
How were TuHURA Biosciences’s earnings last quarter?
TuHURA Biosciences released its earnings results on Aug 14, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.153 by $0.013.
Is TuHURA Biosciences overvalued?
According to Wall Street analysts TuHURA Biosciences’s price is currently Undervalued.
Does TuHURA Biosciences pay dividends?
TuHURA Biosciences does not currently pay dividends.
What is TuHURA Biosciences’s EPS estimate?
TuHURA Biosciences’s EPS estimate is -0.13.
How many shares outstanding does TuHURA Biosciences have?
TuHURA Biosciences has 63,726,616 shares outstanding.
What happened to TuHURA Biosciences’s price movement after its last earnings report?
TuHURA Biosciences reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.153. Following the earnings report the stock price went up 7.391%.
Which hedge fund is a major shareholder of TuHURA Biosciences?
Currently, no hedge funds are holding shares in HURA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TuHURA Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (341.18% Upside)
$9.00 (341.18% Upside)
Hedge Fund Trend
Decreased
By 82.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 7.0%
Last 30 Days ▼ 7.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.30%
Trailing 12-Months
Company Description
TuHURA Biosciences
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.
HURA Stock 12 Month Forecast
Average Price Target
$9.00
▲(341.18% Upside)
Technical Analysis
Agenus
―
Inovio Pharmaceuticals
―
Skye Bioscience
―
Biomea Fusion
―
Cognition Therapeutics
―
Ownership Overview
3.52% Insiders
5.01% Mutual Funds
0.65% Other Institutional Investors
87.07% Public Companies and
Individual Investors